Wegovy Injection: Initial dose (weeks 1 through 4): 0.25 mg subcutaneously once a week Dose escalation: Weeks 5 through 8: 0.5 mg subcutaneously once a week Weeks 9 through 12: 1 mg subcutaneously once a week Weeks 13 through 16: 1.7 mg subcutaneously once a week Alternatively: 1.7 mg subcutaneously once a week Comments: Major adverse cardiovascular (CV) events include CV death, nonfatal myocardial infarction, or nonfatal stroke
Research indicates that GLP-1-associated weight loss follows this expected pattern
In controlled laboratory systems, investigators employ in vitro and animal injury paradigms such as skin wound repair , tendon and ligament damage , muscle degeneration , gastrointestinal inflammation , pulmonary injury , and neuroinflammatory conditions to explore peptideassociated signaling effects (9,10)
Future work may consider the use of 1) a higher dosage of ALCA, 2) smaller test meals, and 3) the use of metabolically normal test subjects in order to further determine the potential antioxidant benefits of ALCA in relation to postprandial oxidative stress and associated biomarkers
PCNA positive cells were observed in multi-layered epithelium in the galactose diet-loaded model, suggesting that abnormal cell proliferation is involved in cataracts 71
